drugset / Trial / NCT03270059
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Phase 2
Recruiting
150 enrolled
OHSU Knight Cancer Institute
Celgene Corporation · collabOregon Health and Science University · collab
RandomizedParallel-groupOpen-labelDiagnostic
Summary
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.
Timeline
- Start
- 2017-10-06
- Primary completion
- 2027-12-15
- Completion
- 2028-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferumoxytol | Diagnostic / imaging agent | — | Intravenous |
| Subject | Gadolinium | Diagnostic / imaging agent | — | Intravenous |